Altamira Therapeutics Ltd. (CYTO) Q2 2024 Earnings Call Transcript

Altamira Therapeutics Ltd. (NASDAQ:CYTO) Q2 2024 Results Conference Call September 24, 2024 8:30 AM ET

Company Participants

Thomas Meyer – Founder, Chairman & Chief Executive Officer
Covadonga Paneda – Chief Operating Officer

Conference Call Participants

Hunter Diamond – Diamond Equity

Operator

Good morning, and welcome to the Altamira Therapeutics First Half 2024 and Business Update Conference Call. On today’s call are Thomas Meyer, Altamira’s Founder, Chairman and Chief Executive Officer; and Covadonga Paneda, Altamira’s Chief Operating Officer.

Earlier today, Altamira issued a news release with the first half 2024 financial results as well as comprehensive business update. The release is available on the Company’s website at www.altamiratherapeutics.com and has been filed with the SEC.

During today’s call, the Company will be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements that address future operating, financial or business performance or its strategies or expectations.

Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results developments and business decisions to differ materially from those contemplated by these statements.

These risks and uncertainties include, but are not limited to, the timing and conduct of our clinical trials, the clinical unity of our product candidates, the timing or likelihood of regulatory filings and approvals our intellectual property position and our financial position as well as those described in the Risk Factors section in our annual report on Form 20-F and future filings with the Securities and Exchange Commission.

In addition, any forward-looking statements represent the Company’s views only as of today and should not be relied upon as representing its views as of any subsequent date. While it may elect to update these future forward-looking statements at some point in the future, it specifically disclaims any obligation